Compass pathways stock forecast.

CMPS Stock 12 Months Forecast. Based on 6 Wall Street analysts offering 12 month price targets for COMPASS Pathways in the last 3 months. The average price target is $50.17 with a high forecast of $120.00 and a low forecast of $21.00. The average price target represents a 832.53% change from the last price of $5.38. According to 5 stock analysts, the average 12-month stock price forecast for CMPS stock stock is $49.6, which predicts an increase of 668.99%. The lowest target is $19 and the highest is $120. On average, analysts rate CMPS stock stock as a strong buy.TipRanksThe latest price target for Compass Pathways ( NASDAQ: CMPS) was reported by Cantor Fitzgerald on Tuesday, August 22, 2023. The analyst firm set a price target for 21.00 expecting CMPS to rise to ...WebHere are some of the best psychedelic sector stocks generating a buzz among investors: — Atai Life Sciences NV (ticker: ATAI) — GH Research PLC ( GHRS) — Compass Pathways PLC ( CMPS ...

But buying the stock now could leave the door open for potentially massive upside in a few years if it can get COMP360 on the market. 2. Atai Life Sciences. Much like Compass Pathways, Atai Life ...

Summary. BiotechValley Insights is initiating coverage of COMPASS Pathways with a "Bearish" rating at a $13 PT. CMPS has filed an IPO with an initial valuation of US$544M; since then, the stock ...

TipRanksThe financials. The average price target from the nine analysts following COMPASS pathways is $68 against a current price of $14.9, implying a 356% upside and a target market cap of $3 billion. I ...The average price target is $46.83, with a high forecast of $120.00 and a low forecast of $19.00. ... The current consensus among 5 investment analysts is to buy stock in COMPASS Pathways. This Buy consensus rating has held steady for over two years. Past Monthly Recommendations.See COMPASS Pathways plc (CMPS) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. COMPASS Pathways (CMPS) Stock Forecast & Price Target $5.93 -0.05 (-0.84%) (As of 11/29/2023 ET) Compare Today's Range $5.84 $6.25 50-Day Range …

Despite the potential of EVgo, Inc. (EVGO), Amyris, Inc. (AMRS), and COMPASS Pathways plc (CMPS) springing a surprise during the earnings season, their less-than-ideal fundamentals deem it wise to avoid placing any long-term bets on these heavily shorted stocks.In 2021, easy money, unprecedented hype created by retail …

The average price target is $46.83, with a high forecast of $120.00 and a low forecast of $19.00. ... The current consensus among 5 investment analysts is to buy stock in COMPASS Pathways. This Buy consensus rating has held steady for over two years. Past Monthly Recommendations.

The average Compass stock price prediction forecasts a potential upside of 35.39% from the current COMP share price of $2.43. What is COMP's forecast return on equity (ROE) for 2023-2026? ( NYSE : COMP ) forecast ROE is N/A , which is considered weak . Can Compass Pathways' Stock Gain 458% Like Wall Street Is Expecting? This Regulatory Change Means Psychedelic Stocks Are One Step Closer to Being a …Nov 13, 2023 · Future criteria checks 0/6. COMPASS Pathways's earnings are forecast to decline at 2.7% per annum while its annual revenue is expected to grow at 82.4% per year. EPS is expected to grow by 6.1% per annum. Return on equity is forecast to be -82.5% in 3 years. 49.33R USD +43.50 +746.20%. The 6 analysts offering 1 year price forecasts for COMPASS Pathways Plc - American Depository Shares have a max estimate of 120.00 …US20451W1018. Compass Pathways Plc is an investment holding company. It operates through its subsidiaries which provide mental health care services. The company was founded by Goldsmith George Jay and Malievaskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom. Show more.COMPASS Pathways Announces Up to $285 Million Private Placement Financing Joined by Leading Healthcare Investors. Transaction led by healthcare specialist investors, TCGX and Aisling Capital. Net ...Web

Asset Growth. -34.43%. Trailing 12-Months. The COMPASS Pathways Holdings stock analysis is based on the TipRanks Smart Score which is derived from 6 unique data sets including Analyst recommendations, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system …16 ส.ค. 2566 ... ... Price” requirement (as defined in the Nasdaq rules). COMPASS intends to use the net proceeds from the proposed financing to fund its pivotal ...COMPASS Pathways' (NASDAQ:CMPS) Phase 2b study of synthetic psilocybin COMP360 paired with psychological support for Treatment-Resistant ... COMPASS Pathways' (NASDAQ:CMPS) Phase 2b study of synthetic psilocybin COMP360 paired with...Future criteria checks 0/6. COMPASS Pathways's earnings are forecast to decline at 2.7% per annum while its annual revenue is expected to grow at 82.4% per year. EPS is expected to grow by 6.1% per annum. Return on equity is forecast to be -82.5% in 3 years.Current. -$0.61. 1 Month Ago. -$0.60. 3 Months Ago. -$0.65. COMPASS Pathways PLC ADR analyst estimates, including CMPS earnings per share estimates and analyst recommendations.Web

The latest price target for Compass Pathways ( NASDAQ: CMPS) was reported by Cantor Fitzgerald on Tuesday, August 22, 2023. The analyst firm set a price target for 21.00 expecting CMPS to rise to ...WebCompass shares are also dragging in late 2023, down 26.3% on a year-to-date basis. The U.K.-based biotech, which specializes in psilocybin research for treating depression, recently landed $285 ...

Stock Price Forecast. The 9 analysts offering 12-month price forecasts for Compass Inc have a median target of 2.70, with a high estimate of 5.00 and a low estimate of 2.00. The median estimate ...WebQuite a few analysts cover the stock, so you could look into forecast growth quite easily. Insider Ownership Of COMPASS Pathways The definition of company insiders can be subjective and does vary ...NasdaqGS:CMPS Earnings and Revenue Growth April 12th 2021. COMPASS Pathways is not owned by hedge funds. Our data shows that ATAI Life Sciences AG is the largest shareholder with 22% of shares ...Of course COMPASS Pathways may not be the best stock to buy. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks that insiders are buying .Compass Pathways plc is followed by the analysts listed. Please note that any opinions, estimates or forecasts regarding Compass Pathways plc's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Compass Pathways plc or its management.Canaccord Genuity analyst Sumant Kulkarni gives the biotech company an $80 price target....CMPS Compass Pathways (CMPS) has grabbed the interest of Canaccord Genuity analyst Sumant Kulkarni, who gave the biotech company an $80 price target....

Detailed statistics for COMPASS Pathways plc (CMPS) stock, including valuation metrics, financial numbers, share information and more. Detailed statistics for COMPASS Pathways plc (CMPS) stock, including valuation metrics, financial numbers, share information and more. ... Analyst Forecast. The average price target for CMPS is …Web

The current Compass Pathways PLC [ CMPS] share price is $6.10. The Score for CMPS is 44, which is 12% below its historic median score of 50, and infers higher risk than normal. CMPS is currently trading in the 40-50% percentile range relative to its historical Stock Score levels.

About the COMPASS Pathways Plc stock forecast. As of 2023 November 27, Monday current price of CMPS stock is 6.450$ and our data indicates that the asset price has been in a downtrend for the past 1 year (or since its inception).. Compass Pathways Plc - ADR stock price has been showing a declining tendency so we believe that similar market …WebCOMPASS PATHWAYS AKTIE und aktueller Aktienkurs. Nachrichten zur Aktie COMPASS Pathways PLC (spons. ADRs) | A2QCDR | CMPS | US20451W1018Learn More. Market Cap. (-2.86%) -$0.17. Current Price. The biotech is developing a treatment paradigm combining talk therapy with a purified version of psilocybin, the active ingredient in "magic ...9 พ.ย. 2564 ... Compass Pathways stock plunged, despite the company reporting that a strong dose of a psilocybin-based drug helped reduce depression.A company's cash runway is the amount of time it would take to burn through its cash reserves at its current cash burn rate. As at September 2021, COMPASS Pathways had cash of US$294m and no debt ...WebNov 9, 2021 · What happened. Compass Pathways ( CMPS 6.61%) saw its shares drop more than 22% on Tuesday. The biotech stock, which focuses on mental health treatment, closed at $43.06 on Monday, opened at $40. ... COMPASS Pathways plc (COMPASS) operates as a mental health care company. The company engages in the development of a new model of psilocybin therapy, in which its investigational COMP360 psilocybin is administered in conjunction with psychological support. Its initial focus is on treatment-resistant depression (TRD), a subset of major ... COMPASS Pathways - Overview (February Company Presentation) Recent Events: Compass posted fourth quarter results one week ago. The company posted a net loss of $25.7 million for the quarter and ...Compass Pathways (NASDAQ: CMPS) is owned by 35.95% institutional shareholders, 57.27% Compass Pathways insiders, and 6.79% retail investors. Ekaterina Malievskaia is the largest individual Compass Pathways shareholder, owning 12.82M shares representing 20.71% of the company. Ekaterina Malievskaia's Compass Pathways shares are …Discover COMPASS Pathways' earnings and revenue growth rates, forecasts, and the latest analyst predictions while comparing them to its industry peers.COMPASS Pathways is a mental healthcare company that specializes in psilocybin therapy. Read more to see my thoughts on CMPS stock and why it is a Hold. ... CMPS Stock Forecast.Web

Can Compass Pathways' Stock Gain 458% Like Wall Street Is Expecting? Wall Street might have the timing wrong, but their hopes aren't misplaced. Alex Carchidi | Jul 1, 2023Hedge funds don't have many shares in COMPASS Pathways. Our data shows that Atai Life Sciences N.V. is the largest shareholder with 23% of shares outstanding.Apr 20, 2023 · With its shares down by 60% in the last 12 months and a recent layoff affecting 30% of its workforce, it's fair to say that Atai Life Sciences ( ATAI 1.87%) is having a rough go of things lately ... CMPS Earnings Date and Information. COMPASS Pathways last posted its quarterly earnings results on November 2nd, 2023. The reported ($0.67) EPS for the quarter, missing the consensus estimate of ($0.50) by $0.17. COMPASS Pathways has generated ($2.59) earnings per share over the last year ( ($2.59) diluted earnings per share).Instagram:https://instagram. online penny stock brokersibkr fx tradinginstant debit card onlinevanguard growth Aug 26, 2023 · Beam Therapeutics (BEAM-1.72%), COMPASS Pathways (CMPS-6.05%), ... The average price target for the stock is $41.67, implying a 382% upside potential from its current share price. Like Beam ... Stock analysis for Compass Pathways Plc (CMPS:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. vz dividendssmg ticker Despite the potential of EVgo, Inc. (EVGO), Amyris, Inc. (AMRS), and COMPASS Pathways plc (CMPS) springing a surprise during the earnings season, their less-than-ideal fundamentals deem it wise to avoid placing any long-term bets on these heavily shorted stocks.In 2021, easy money, unprecedented hype created by retail … tsla stock options Find the latest analyst research for COMPASS Pathways Plc American Depository Shares (CMPS) at Nasdaq.com.WebOn May 2, COMPASS Pathways (CMPS 6.61%) announced that the American Medical Association (AMA) ... This Unexpected Development Is Yet Another Green Flag for Compass Pathways Stock.21.61M. MSFT. 377.43. -0.11%. 9.38M. View today's Compass Pathways Plc stock price and latest CMPS news and analysis. Create real-time notifications to follow any changes …